 | FY2019 EPS Estimates for H. Lundbeck A/S- (OTCMKTS:HLUYY) Boosted by Analyst
www.americanbankingnews.com - November 11 at 3:20 AM |
| Q4 2019 EPS Estimates for H. Lundbeck A/S- Decreased by Analyst (OTCMKTS:HLUYY)
www.americanbankingnews.com - November 8 at 6:46 PM |
 | Alpha Synuclein Market Competitive Analysis With Growth Forecast Till 2025
www.marketwatch.com - November 8 at 1:52 PM |
 | H. Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q3 2019 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 1:18 PM |
| H. Lundbeck A/S 2019 Q3 - Results - Earnings Call Presentation
seekingalpha.com - November 5 at 1:06 PM |
 | Danish drugmaker Lundbeck ups profit outlook on improved sales
www.reuters.com - November 5 at 8:05 AM |
| H. Lundbeck A/S reports 9M results
seekingalpha.com - November 5 at 8:05 AM |
 | UPDATE 1-Lundbeck hikes profit outlook, eyes return to growth in 2020
finance.yahoo.com - November 5 at 8:05 AM |
| Alzheimer's Disease Treatments Market May Set New Growth Story | Eisai, Forest Laboratories
www.marketwatch.com - November 4 at 2:02 PM |
| Alzheimers Therapeutics Market to Eyewitness Massive Growth by 2025
www.marketwatch.com - November 2 at 2:00 PM |
| Alzheimers Drug Market Latest Innovations, Drivers and Forecast to 2030
www.marketwatch.com - October 31 at 8:54 AM |
| Antipsychotic Drugs Market to Reach US$ 20,539.5 Mn by 2026; Schizophrenia Segment to Witness Rapid Growth
www.marketwatch.com - October 23 at 4:30 AM |
| Parkinson's Disease Drug Market Insights and Global Outlook During 2019-2025
www.marketwatch.com - October 18 at 3:39 PM |
| The H. Lundbeck (CPH:LUN) Share Price Has Gained 97% And Shareholders Are Hoping For More
finance.yahoo.com - October 9 at 12:34 PM |
| Antidepressants Market Future Lookout by Top Key Players H Lundbeck, Astrazeneca, Eli Lilly and Company, Sun Pharmaceuticals
www.marketwatch.com - October 4 at 4:05 PM |
| Antidepressants Market Report by Recent Trends, Major Driving Factors and Business Growth Strategies and Forecast 2024
www.marketwatch.com - October 1 at 7:38 AM |
| Global General Anxiety Disorder Market To Flourish And Reach USD 3,775 million By 2024
www.marketwatch.com - September 30 at 4:12 PM |
| Alzheimer's Drugs Market forecasting 2019 - 2030 by Trends, Growth, Share, Distribution Channel, Key Players & Analysis
www.marketwatch.com - September 23 at 11:50 PM |
| Lundbeck Makes A Large M&A Move, But The Target Will Be Somewhat Controversial
seekingalpha.com - September 18 at 5:30 AM |
| SHAREHOLDER ALERT: WeissLaw LLP Investigates Alder Biopharmaceuticals, Inc.
finance.yahoo.com - September 18 at 5:30 AM |
| Does H. Lundbeck A/S's (CPH:LUN) P/E Ratio Signal A Buying Opportunity?
finance.yahoo.com - September 9 at 8:21 AM |
| Memantine Industry 2019 Market Size, Segments, Key Regions, Future Scope, Growth Factors, Company Profiles and Forecast till 2026
www.marketwatch.com - September 7 at 10:27 AM |
| What are the key Player impacting the growth of the Hydroxytryptamine Receptor market?
www.marketwatch.com - August 27 at 5:08 PM |
| Lundbeck's M&A Flexibility May Be Its Greatest Asset Today
seekingalpha.com - August 20 at 5:24 PM |
| Alzheimer’s Drugs Market 2019-2030 | Prominent Players F.Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, AC Immune, Novartis AG, El.En. S.P.A
www.marketwatch.com - August 20 at 9:02 AM |
| Is There An Opportunity With H. Lundbeck A/S's (CPH:LUN) 42% Undervaluation?
finance.yahoo.com - August 20 at 9:02 AM |
| H. Lundbeck A/S 2019 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 14 at 10:10 AM |
| Is H. Lundbeck (HLUYY) a Profitable Pick for Value Investors?
finance.yahoo.com - August 14 at 10:10 AM |
| What Can We Expect From H. Lundbeck A/S's (CPH:LUN) Earnings In Next 12 Months?
finance.yahoo.com - July 29 at 9:15 AM |
| What Can We Expect From H. Lundbeck A/S's (CPH:LUN) Earnings In Next 12 Months?
finance.yahoo.com - July 29 at 9:15 AM |
| Global Alzheimer's Therapeutics Market 2019 exhibiting a CAGR of 8.20%
www.marketwatch.com - July 10 at 10:33 AM |
| Do Directors Own H. Lundbeck A/S (CPH:LUN) Shares?
finance.yahoo.com - July 9 at 10:39 AM |
| Is H. Lundbeck A/S (CPH:LUN) As Strong As Its Balance Sheet Indicates?
finance.yahoo.com - June 19 at 10:22 AM |
 | Cerecor Appoints Keith Schmidt to its Board of Directors
www.globenewswire.com - June 12 at 6:54 PM |
| Parkinson's Disease Drug Market Projected to Show Strong Growth | Merck, Akorn, GSK, Novartis, Boehringer Ingelheim
www.marketwatch.com - June 9 at 4:14 PM |
| Does H. Lundbeck A/S (CPH:LUN) Have A Place In Your Dividend Portfolio?
finance.yahoo.com - May 30 at 10:35 AM |
| Anti-Epileptic Drugs Market Key Manufactures and Opportunity Analysis By 2024
www.marketwatch.com - May 29 at 5:06 PM |
| What Do Analysts Think About H. Lundbeck A/S's (CPH:LUN) Earnings Trend?
finance.yahoo.com - May 10 at 10:38 AM |
| What Do Analysts Think About H. Lundbeck A/S's (CPH:LUN) Earnings Trend?
finance.yahoo.com - May 10 at 10:38 AM |
| Lundbeck, Like The Dude, Will Try To Abide
seekingalpha.com - May 9 at 5:10 PM |
| Heed Analysts' Advice on Lundbeck: Sit Tight
finance.yahoo.com - May 9 at 10:33 AM |
 | Lundbeck to Buy Abide Therapeutics for Up to $400 Million
www.wsj.com - May 7 at 10:31 AM |
| H. Lundbeck scoops up Abide for ~$400M, including milestone payment
seekingalpha.com - May 6 at 5:12 PM |
| Lundbeck scoops up Abide for up to $400M
seekingalpha.com - May 6 at 5:12 PM |
| Lundbeck to acquire Abide Therapeutics, adding a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s
www.globenewswire.com - May 6 at 10:34 AM |
| Anti-Suicide Drugs Market 2019 Global Industry Sales, Supply, Consumption, Demand, Analysis and Forecasts to 2025
www.marketwatch.com - April 29 at 10:23 AM |
| Did You Miss H. Lundbeck's (CPH:LUN) 87% Share Price Gain?
finance.yahoo.com - April 16 at 12:04 PM |
| Drugmakers pay $123 million to resolve U.S. charity kickback probe
finance.yahoo.com - April 4 at 10:46 AM |
| Benzodiazepine Market Share Analysis, Strategies, Revenue and Forecasts to 2022
www.marketwatch.com - March 28 at 11:10 AM |
| Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development
finance.yahoo.com - March 20 at 10:09 AM |
